AstraZeneca Brilinta (Tikagrelor) 90mg In Pakistan

AstraZeneca Brilinta (Tikagrelor) 90mg In Pakistan

AstraZeneca Brilinta 90mg Tablets contain ticagrelor, an oral antiplatelet medicine that inhibits platelet activation. It is used in specific cardiovascular conditions, particularly acute coronary syndrome (ACS), to reduce the risk of cardiovascular events such as heart attack and cardiovascular death. It may also be used in selected patients with acute ischemic stroke or high-risk TIA according to the applicable prescribing information.

Brilinta works by reversibly blocking the platelet P2Y12 ADP receptor, helping reduce platelet aggregation and formation of harmful blood clots.

Benefits

• Contains ticagrelor 90mg.
• Helps reduce platelet activation and clot formation.
• Used in appropriate patients with acute coronary syndrome.
• May reduce the risk of cardiovascular events when prescribed appropriately.
• Can reduce the risk of stent thrombosis in certain ACS patients undergoing stenting.
• Available as a convenient oral tablet formulation.

Specifications

Brilinta 90mg is supplied as a round, biconvex, yellow film-coated tablet in the referenced prescribing information.

How To Use

Brilinta 90mg should be taken exactly as prescribed by your cardiologist or other qualified healthcare professional. The dose and duration depend on the medical indication.

For ACS, the referenced prescribing information specifies an initial 180mg loading dose, followed by 90mg twice daily during the first year. Brilinta is generally used with low-dose aspirin when prescribed for ACS; the appropriate aspirin dose should be determined by the treating physician.

• Take the tablet orally as prescribed.
• Take doses at approximately the same times each day.
• Do not stop Brilinta suddenly without medical advice because interruption can increase cardiovascular risk.
• Tell your doctor and dentist that you are taking ticagrelor before procedures or surgery.
• If you miss a dose, follow the prescribed instructions rather than taking an extra dose.

Important Safety Information

Brilinta can significantly increase the risk of bleeding, including serious or potentially fatal bleeding. It is contraindicated in patients with active pathological bleeding or a history of intracranial hemorrhage.

Other important adverse effects can include shortness of breath (dyspnea) and bleeding/bruising. Tell your healthcare provider about all medicines you take because ticagrelor has important drug interactions, including with strong CYP3A inhibitors and inducers.

Seek urgent medical attention for severe or uncontrolled bleeding, blood in the urine or stool, vomiting blood, severe breathing difficulty, or other serious symptoms.

Why Choose Brilinta 90mg?

• Contains the established antiplatelet ingredient ticagrelor.
• Manufactured by AstraZeneca.
• Works directly on the platelet P2Y12 receptor.
• 90mg strength is used in specific treatment regimens, particularly following ACS.
• Oral formulation for convenient administration.
• Treatment can be monitored and adjusted by a qualified cardiovascular specialist.